IBM enters May with an unusual dynamic: short sellers are quietly stepping back just weeks after the stock suffered one of its worst single-session earnings drops in recent memory.
Q1 results on April 22 sent the stock down 9.6% the following day. The five-day loss extended to 11.2%. Yet in the aftermath, rather than pressing their advantage, shorts have been covering. SI as a % of the free float has fallen from a local peak of 2.54% around the earnings date to 2.29% now — a steady, daily grind lower across twelve consecutive sessions. The stock trades at $229.03, down 7.7% over the past month and off 1.7% on the week.
The lending market offers little drama to support a sustained short thesis. Cost to borrow is just 0.54% — barely above risk-free — and has barely budged despite the share-price weakness. Availability in the borrow pool remains abundant, meaning there is no structural squeeze pressure or scarcity in the lending market. The ORTEX short score has eased from 35.8 in late April to 33.7 today, drifting away from territory that typically flags elevated short conviction. Options positioning is similarly unhurried: the put/call ratio at 0.85 is almost exactly in line with its 20-day average of 0.83, with a z-score of just 0.64 — options traders are neither aggressively hedging nor loading up on calls.
The analyst community is mixed on what happens next, but the direction of travel on targets is clear: down. RBC Capital trimmed its target to $300 from $330 today while holding its Outperform rating. Morgan Stanley, which carries an Equal-Weight, actually nudged its target modestly higher to $225 — close to where the stock is trading — underscoring the wide gap between the cautious and the bullish camps. Wedbush reiterated its $320 Outperform. Evercore ISI and Jefferies, both buyers, cut targets to $310 and $320 respectively. HSBC moved from Reduce to Hold after the earnings selloff, lifting its target to $231. The mean price target across the Street sits at $278, roughly 21% above the current price — though that gap widened because the stock fell, not because targets rose. The forward earnings yield factor ranks in the 46th percentile; EPS momentum over the past 90 days sits in the 38th percentile. The one standout: IBM's analyst recommendation differential ranks in the 98th percentile, meaning relative to the universe it attracts unusually bullish ratings — but that score increasingly reflects consensus inertia rather than fresh conviction given the string of target cuts.
The bull case rests on IBM's AI and hybrid cloud transition, anchored by Red Hat and Watson, alongside a steady dividend and consulting relationships across regulated industries. The bear case centres on a slower-than-expected return on its rising capital expenditure, pressure on consulting margins, and the difficulty of demonstrating top-line reacceleration against nimbler competitors. The NHS App contract win in the UK this week is a small positive data point for the consulting book, but it is a single contract in a difficult period.
Among correlated peers, CTSH fell 5.9% on the week while EPAM dropped 4.0% — suggesting broad pressure across the IT services sector rather than IBM-specific pain. DXC was the outlier, gaining 2.9%, reflecting its different exposure mix. The next earnings date is July 22. Between now and then, the question for positioning is whether the Street's target-cutting cycle has run its course, or whether the gap between buy-side optimism and current price simply reflects a stock that needs time to earn back credibility after the Q1 miss.
See the live data behind this article on ORTEX.
Open IBM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
